Objective: De novo mutations contribute significantly to severe early-onset genetic disorders.
| INTRODUCTION
Over the past few years, it has been demonstrated that de novo mutations play a prominent part in rare and common forms of neurodevelopmental disorders. 1, 2 In common clinical practice, a mutation is considered de novo if the mutation can be detected by
Sanger sequencing in peripheral blood of the proband, but not in either of the parents. After birth of a child with a genetic disease caused by a de novo mutation, the recurrence risk of the condition in a future offspring will vary depending on the gonadal generation in which the mutation occurred. A mutation in a germline cell early in development can produce a large clone of mutant germ cells and result in germline mosaicism (also called gonadal mosaicism). De novo mutations can also occur in the early stage of embryonic development. Depending on the timing of the postzygotic mutation during development, such mutations may lead to somatic or germline mosaicism or both (for review see Forsberg et al). 3 Germline mosaicism is usually only confirmed if parents have more than one child with the same genetic disorder and both parents are not affected or carriers of the condition.
Parental germline mosaicism has now been reported for a wide range of disorders. 4, 5 This group of disorders comprises various conditions that typically are autosomal dominant but occasionally manifests with an autosomal recessive inheritance where one parent is gonadal mosaic and the other has a germline variant in the same gene. 6 Recent studies, using more sensitive technologies such as next generation sequencing and genomic microarrays, have suggested that mosaicism in somatic tissues of apparently healthy parents are more common than previously thought. 4 Such somatically mosaic parents might also have germline mosaicism that potentially can cause recurrence. The presence of germline mosaicism complicates genetic counseling and usually an empiric risk is quoted. The recurrence risk for future offspring after birth of an affected child may be as high as 50% if one of the apparently healthy parents is mosaic. It is possible to investigate if the unaffected father is producing a proportion of mutant sperm; however, this is only performed at research basis.
Genetic testing of female germline is not feasible and is therefore limited to somatic tissues, e.g. skin fibroblasts or hair root. In common practice, the couples are usually offered prenatal diagnosis in the next pregnancy to identify affected fetuses, if the disease-causing variant is known. Germline mosaicism is assumed if two or more pregnancies with the same deviations have occurred and preimplantation genetic diagnosis (PGD) may then be available to help these couples identify embryos carrying the genetic disease, thus avoiding affected offspring.
For PGD, it is important to know the parental origin of the mutation to increase the chance to identify an unaffected embryo. Mutation detection alone cannot be applied in PGD, as allelic drop out is common when analyzing one or a few cells. PGD is therefore routinely done by linkage analysis and mutation detection. 7 The limitations are that several affected fetuses are needed to identify informative markers for linkage analysis and haplotypes can be difficult to define because of the short read length of Sanger sequencing (up to 1000 bp).
In this study, we demonstrate the power of using single-molecule real time (SMRT) sequencing and Droplet Digital PCR (ddPCR) to identify the parental origin of de novo mutations in two families that had undergone assisted reproduction and PGD, respectively, with the specific aim to investigate the recurrence risk or to facilitate PGD.
In the first family, the couple had undergone assisted reproduction with oocyte donation, and the biological mother was unknown. TCS has an extreme inter and intra familial phenotypic variability.
Approximately 60% of individuals have the disorder because of a de novo mutation, and approximately 40% of the individuals diagnosed with TCS have an affected parent. A case of suspected germ line mosaicism of a TCOF1 mutation has previously been reported.
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In the second family, the couple had undergone 4 pregnancies, two spontaneous miscarriages, and two terminated pregnancies due to ultrasound aberrations. The two fetuses from the terminated pregnancies were subjected for genetic testing, and a previously reported PTPN11 mutation c.923A>C (p.Asn308Thr) 12 associated with Noonan syndrome (NS) was identified in both affected fetuses. NS is a heterogeneous developmental disorder with a variable clinical expression including short stature, congenital heart defect, unusual pectus deformity, and typical facial features. 13, 14 It is caused by autosomal dominant activating mutations in genes involved in the RAS-MAPK signaling pathway, [15] [16] [17] [18] [19] [20] [21] and approximately 50% of the cases are associated with mutations in PTPN11. 22 Although many individuals with NS have a de novo pathogenic variant, an affected parent is recognized in 30% to 75% of families, and many are diagnosed first after the diagnosis of the affected child. When the parents are clinically unaffected, the recurrence risk appears to be low (<1%).
In both families, carrier analysis of peripheral blood from the available biological parents revealed that none were carrier of the variants. To investigate the families further, we have utilized the advantages of SMRT sequencing by its extensive read lengths and depth. We could uncover the pathogenic effect of the VUS in TCOF1
as well as to determine parental origin and the allele frequencies of the mutated alleles in both PTPN11 and TCOF1. The allele frequencies were also verified by using ddPCR on DNA from sperm. following Sanger sequencing and analysis as previously described. and analysis according to standard conditions as previously described on gDNA in both forward and reverse direction (forward primer: 5′-CAG CCA TTT GAG CTC CCT GA-3′ and reverse primer: 5′-CTG GCC TCC TAG CTA CAA CC-3′) generating a 511 bp product.
| Preimplantation genetic diagnosis (PGD)
The couple opted for PGD even though the origin of the mutation had not been determined at that point. PGD was offered and performed with the strategy to perform linkage analysis and transfer embryos that had inherited both the alternative maternal and alternative paternal haplotype as compared with the affected fetuses. In theory, 25% of the embryos would be possible to transfer. Four PGD cycles were conducted from October 2014 until November 2015:
1. Three embryos, one unaffected, transfer, no pregnancy.
2. Six embryos, one unaffected, transfer, no pregnancy.
3. Two embryos, none unaffected.
4. Two embryos, none unaffected.
For cycle 2, 3, and 4, one additional embryo had been possible to transfer if the carriership had been known at that point, because the embryo had inherited the "healthy" paternal allele.
2.4 | Investigation of haplotype ancestry and gonadal mosaicism using SMRT sequencing 
| Identification of disease-causing variant
DNA from the affected child was subjected to Sanger sequencing of the TCOF1 gene. Data revealed six variants (Supplementary Table   S1 ), five were considered as benign, and one heterozygous variant of uncertain significance (VUS) c.3156C>T (p.Gly1052Gly) at position chr5:149769559 (exon 19) in the TCOF1 gene (NM_001135244) was identified ( Figure 1B) . The variant is predicted to create a new splice donor site and affect the protein structure by causing a premature termination codon. The variant has been implicated as a potential disease-causing variant in TCS once before; however, its effect on splicing remained to be proven. 23 The variant was not identified in the father's blood ( Figure 1B ) and has not been reported 
A recurrent heterozygous mutation in PTPN11 c.923A>C (p. Sanger sequencing, but not in the parental blood ( Figure 1D ). This mutation is previously described as pathogenic causing NS.
| Investigation of haplotype ancestry and gonadal mosaicism with SMRT sequencing
SMRT sequencing on the PacBio system was performed in both families to investigate the parental origin of the mutations in TCOF1
and PTPN11, by searching for variants located adjacent to the mutation. For the TCS family, only the father's and child's DNA was investigated, whereas for the NS family, the mother, father, and affected child were analyzed. In the TCS family, a total of five variants were identified (rs79012265, rs77558738, c.3156C>T, rs2295223 and rs8004246). A total of 249 (48.1%) vs 269 (51.9%) reads, respectively, defined the child's haplotype, and 1839 reads spanned the father's haplotype a total region of 3.8 kb. The sequence variant c.3156C>T
was identified on the father's haplotype (Table 1) . For the NS family, no informative variants were detected, and therefore no result regarding haplotype origin was obtained. The region analyzed were 3.9 kb in size with a coverage of 1975-4167 X (data not shown).
SMRT sequencing was performed in duplicates to investigate low-frequency occurrence of gonadal mosaicism in the father's sperm from both the TCS and NS families. SMRT sequencing on the Pacific
Bioscience system generated between 1454 and 3275 reads. For the TCS family, one mutated read, c.3156C>T, was identified in both runs, giving a frequency below detection rate for occurrence. For the NS family, 576 and 1201 reads for each run identified the variant c.923A>C, estimating a frequency of 36.6 to 37.1% in the sperm (Table 2 ).
| ddPCR screening for replication and frequency estimation
To confirm the results, estimate recurrence risk and the accuracy of previously obtained allele frequencies from SMRT sequencing, ddPCR was performed in triplicates on all available samples from both families. For the TCS family, the index patient had a total of 49.7% of mutation positive droplets and 50.3% wild-type positive droplets, which is expected for a heterozygous individual. Blood and sperm from the father had 0% positive droplets likewise a healthy control sperm sample included (Figure 3 ; Supplementary Table S2 ). The recurrence risk for the TCS family, using the same oocyte donor, is therefore extremely small, based on that no mutation positive droplets were identified in the father's sperm. For the NS family, the heterozygous index patient had a total of 50.3% of mutation positive droplets and 49.7% wild-type positive droplets.
The blood samples from the mother and father were negative, with 0% mutated droplets identified. However, in the sperm sample from the father, 40% mutated droplets and 60% wild-type reads were identified. The risk of recurrence was therefore estimated to be 40%
( Figure 3 ; Supplementary Table S2 ).
| DISCUSSION
De novo mutations in human disease have many implications for routine genetic testing and clinical practice. They are the cause of disease in a large fraction of patients with severe early-onset disorders, such as rare congenital malformation syndromes, 24, 25 and neurodevelopmental disorders (intellectual disability, 26 epilepsy, 27 and autism spectrum disorders 28 ). These disorders represent a large proportion of all patients seen at the clinics worldwide.
Current techniques (e.g. standard Sanger sequencing), widely used in diagnostic laboratories have limitations because they are unable to distinguish between haplotype origins and to detect mutation frequencies at a low level. With the introduction of massively parallel sequencing technologies, it is now possible to study mutations at a new level of resolution. Next generation sequencing technologies allow identification at an increased depth and accuracy than previously. SMRT sequencing from Pacific Biosciences has been developed to produce long and highly accurate DNA sequences from individual molecules. 29, 30 Its use has previously been mainly implicated in de novo genome assemblies, but is now being increasingly used for clinical analyses such as detection of somatic revertant mosaicism, 31 quantification of BCR-ABL transcripts in chronic myeloid leukemia (CML), 32 and studying FMR1 repeat expansions in the fragile X syndrome. 33 The PacBio system provides sufficiently long reads to determine haplotype origin and depth to detect mutation frequencies at a level of 1%. In addition, ddPCR system allows for an absolute quantification, high throughput, high sensitivity, and high precision with mutation detection reliability below 1%. Average number of droplets (Nb) FIGURE 3 Droplet Digital PCR (ddPCR) to estimate recurrence risk and in triplicates on all samples from the Treacher Collins syndrome and Noonan syndrome families. For the Noonan syndrome family (in blue), the heterozygote index patient had a total of 50.3% of mutation positive droplets (dark blue) and 49.7% wild-type positive droplets (light blue). The blood samples from the mother and father were negative, with 0% mutated droplets identified. Sperm sample from the father identified 40% mutated droplets (dark blue) and 60% wild-type reads (light blue). The risk of recurrence was estimated to be 40%. For the TCS family (in red), the index patient had a total of 49.7% of mutation positive droplets (dark red) and 50.3% wild-type positive droplets (light red). Blood and sperm from the father had 0% positive droplets as well as the healthy control sperm sample included in the study [Colour figure can be viewed at wileyonlinelibrary.com]
| CONCLUSIONS
Our results emphasize a strategy to identify the parental origin and investigate the recurrence risk of pathogenic mutations with the introduction of massively parallel sequencing technologies into a clinical setting. These methods will be successful for couples that have undergone assisted reproduction with an unknown donor or in couples with gonadal mosaicism that will undergo PGD.
